Which has better earnings & valuation, NVCR or BWAY?

Brainsway has lower revenue, but higher earnings than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NovoCure $655.35M 2.97 -$136.23M -$1.30 N/A Brainsway $52.22M 10.48 $7.57M $0.44 30.93

Is NVCR or BWAY more profitable?

Brainsway has a net margin of 15.65% compared to NovoCure's net margin of -21.25%. Brainsway's return on equity of 12.74% beat NovoCure's return on equity. Company Net Margins Return on Equity Return on Assets NovoCure -21.25% -44.00% -15.85% Brainsway 15.65% 12.74% 8.17%

Does the media refer more to NVCR or BWAY?

In the previous week, NovoCure had 3 more articles in the media than Brainsway. MarketBeat recorded 4 mentions for NovoCure and 1 mentions for Brainsway. Brainsway's average media sentiment score of 0.88 beat NovoCure's score of 0.20 indicating that Brainsway is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NovoCure 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Brainsway 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor BFLY or BWAY?

In the previous week, Butterfly Network had 6 more articles in the media than Brainsway. MarketBeat recorded 7 mentions for Butterfly Network and 1 mentions for Brainsway. Brainsway's average media sentiment score of 0.88 beat Butterfly Network's score of 0.44 indicating that Brainsway is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Butterfly Network 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Brainsway 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, BWAY or LMAT?

LeMaitre Vascular has higher revenue and earnings than Brainsway. LeMaitre Vascular is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Brainsway $52.22M 10.48 $7.57M $0.44 30.93 LeMaitre Vascular $249.60M 7.23 $57.73M $2.85 27.67

Does the media refer more to BWAY or LMAT?

In the previous week, Brainsway and Brainsway both had 1 articles in the media. LeMaitre Vascular's average media sentiment score of 1.63 beat Brainsway's score of 0.88 indicating that LeMaitre Vascular is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Brainsway 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive LeMaitre Vascular 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor INSP or BWAY?

In the previous week, Inspire Medical Systems had 6 more articles in the media than Brainsway. MarketBeat recorded 7 mentions for Inspire Medical Systems and 1 mentions for Brainsway. Inspire Medical Systems' average media sentiment score of 1.23 beat Brainsway's score of 0.88 indicating that Inspire Medical Systems is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inspire Medical Systems 5 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Brainsway 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Brainsway (BWAY) Competitors

$13.61 +0.08 (+0.59%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$13.62 +0.02 (+0.11%)

As of 09/18/2026 07:30 PM Eastern

Compare

BWAY vs. ESTA, NVCR, BFLY, LMAT, and INSP

Should you buy Brainsway stock or one of its competitors? Brainsway's main competitors and comparable companies include Establishment Labs (ESTA), NovoCure (NVCR), Butterfly Network (BFLY), LeMaitre Vascular (LMAT), and Inspire Medical Systems (INSP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Brainsway compare to Establishment Labs?

Brainsway (NASDAQ:BWAY) and Establishment Labs (NASDAQ:ESTA) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends and valuation.

30.1% of Brainsway shares are owned by institutional investors. Comparatively, 72.9% of Establishment Labs shares are owned by institutional investors. 19.0% of Brainsway shares are owned by company insiders. Comparatively, 10.0% of Establishment Labs shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Brainsway had 1 more articles in the media than Establishment Labs. MarketBeat recorded 1 mentions for Brainsway and 0 mentions for Establishment Labs. Establishment Labs' average media sentiment score of 1.67 beat Brainsway's score of 0.88 indicating that Establishment Labs is being referred to more favorably in the news media.

Company	Overall Sentiment
Brainsway	Positive
Establishment Labs	Very Positive

Brainsway has a beta of 1.25, meaning that its share price is 25% more volatile than the broader market. Comparatively, Establishment Labs has a beta of 1.05, meaning that its share price is 5% more volatile than the broader market.

Brainsway currently has a consensus price target of $18.20, suggesting a potential upside of 33.73%. Establishment Labs has a consensus price target of $100.25, suggesting a potential upside of 44.66%. Given Establishment Labs' stronger consensus rating and higher possible upside, analysts clearly believe Establishment Labs is more favorable than Brainsway.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Brainsway	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71
Establishment Labs	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78

Brainsway has higher earnings, but lower revenue than Establishment Labs. Establishment Labs is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Brainsway	$52.22M	10.48	$7.57M	$0.44	30.93
Establishment Labs	$211.08M	9.78	-$51.06M	-$1.31	N/A

Brainsway has a net margin of 15.65% compared to Establishment Labs' net margin of -15.82%. Brainsway's return on equity of 12.74% beat Establishment Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Brainsway	15.65%	12.74%	8.17%
Establishment Labs	-15.82%	-196.69%	-10.73%

Summary

Brainsway beats Establishment Labs on 10 of the 16 factors compared between the two stocks.

How does Brainsway compare to NovoCure?

NovoCure (NASDAQ:NVCR) and Brainsway (NASDAQ:BWAY) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, media sentiment, valuation, profitability and institutional ownership.

NovoCure has a beta of 1.01, suggesting that its stock price is 1% more volatile than the broader market. Comparatively, Brainsway has a beta of 1.25, suggesting that its stock price is 25% more volatile than the broader market.

84.6% of NovoCure shares are held by institutional investors. Comparatively, 30.1% of Brainsway shares are held by institutional investors. 6.6% of NovoCure shares are held by insiders. Comparatively, 19.0% of Brainsway shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

NovoCure currently has a consensus target price of $21.20, suggesting a potential upside of 27.02%. Brainsway has a consensus target price of $18.20, suggesting a potential upside of 33.73%. Given Brainsway's stronger consensus rating and higher possible upside, analysts plainly believe Brainsway is more favorable than NovoCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NovoCure	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14
Brainsway	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71

Brainsway has a net margin of 15.65% compared to NovoCure's net margin of -21.25%. Brainsway's return on equity of 12.74% beat NovoCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NovoCure	-21.25%	-44.00%	-15.85%
Brainsway	15.65%	12.74%	8.17%

Brainsway has lower revenue, but higher earnings than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NovoCure	$655.35M	2.97	-$136.23M	-$1.30	N/A
Brainsway	$52.22M	10.48	$7.57M	$0.44	30.93

In the previous week, NovoCure had 3 more articles in the media than Brainsway. MarketBeat recorded 4 mentions for NovoCure and 1 mentions for Brainsway. Brainsway's average media sentiment score of 0.88 beat NovoCure's score of 0.20 indicating that Brainsway is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NovoCure	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Brainsway	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Brainsway beats NovoCure on 13 of the 16 factors compared between the two stocks.

How does Brainsway compare to Butterfly Network?

Butterfly Network (NYSE:BFLY) and Brainsway (NASDAQ:BWAY) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, earnings, dividends, analyst recommendations, valuation and profitability.

Brainsway has lower revenue, but higher earnings than Butterfly Network. Butterfly Network is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Butterfly Network	$97.61M	21.54	-$77.06M	-$0.29	N/A
Brainsway	$52.22M	10.48	$7.57M	$0.44	30.93

37.9% of Butterfly Network shares are held by institutional investors. Comparatively, 30.1% of Brainsway shares are held by institutional investors. 22.0% of Butterfly Network shares are held by insiders. Comparatively, 19.0% of Brainsway shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Brainsway has a net margin of 15.65% compared to Butterfly Network's net margin of -66.74%. Brainsway's return on equity of 12.74% beat Butterfly Network's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Butterfly Network	-66.74%	-33.99%	-22.96%
Brainsway	15.65%	12.74%	8.17%

Butterfly Network currently has a consensus price target of $6.56, suggesting a potential downside of 16.87%. Brainsway has a consensus price target of $18.20, suggesting a potential upside of 33.73%. Given Brainsway's stronger consensus rating and higher probable upside, analysts plainly believe Brainsway is more favorable than Butterfly Network.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Butterfly Network	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Brainsway	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71

Butterfly Network has a beta of 2.08, suggesting that its share price is 108% more volatile than the broader market. Comparatively, Brainsway has a beta of 1.25, suggesting that its share price is 25% more volatile than the broader market.

In the previous week, Butterfly Network had 6 more articles in the media than Brainsway. MarketBeat recorded 7 mentions for Butterfly Network and 1 mentions for Brainsway. Brainsway's average media sentiment score of 0.88 beat Butterfly Network's score of 0.44 indicating that Brainsway is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Butterfly Network	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Brainsway	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Brainsway beats Butterfly Network on 10 of the 16 factors compared between the two stocks.

How does Brainsway compare to LeMaitre Vascular?

Brainsway (NASDAQ:BWAY) and LeMaitre Vascular (NASDAQ:LMAT) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, media sentiment, dividends, risk, institutional ownership and earnings.

In the previous week, Brainsway and Brainsway both had 1 articles in the media. LeMaitre Vascular's average media sentiment score of 1.63 beat Brainsway's score of 0.88 indicating that LeMaitre Vascular is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Brainsway	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
LeMaitre Vascular	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

30.1% of Brainsway shares are held by institutional investors. Comparatively, 84.6% of LeMaitre Vascular shares are held by institutional investors. 19.0% of Brainsway shares are held by insiders. Comparatively, 7.4% of LeMaitre Vascular shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Brainsway has a beta of 1.25, meaning that its stock price is 25% more volatile than the broader market. Comparatively, LeMaitre Vascular has a beta of 0.5, meaning that its stock price is 50% less volatile than the broader market.

Brainsway presently has a consensus price target of $18.20, indicating a potential upside of 33.73%. LeMaitre Vascular has a consensus price target of $110.60, indicating a potential upside of 40.23%. Given LeMaitre Vascular's higher probable upside, analysts clearly believe LeMaitre Vascular is more favorable than Brainsway.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Brainsway	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71
LeMaitre Vascular	0 Sell rating(s)	6 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

LeMaitre Vascular has higher revenue and earnings than Brainsway. LeMaitre Vascular is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Brainsway	$52.22M	10.48	$7.57M	$0.44	30.93
LeMaitre Vascular	$249.60M	7.23	$57.73M	$2.85	27.67

LeMaitre Vascular has a net margin of 25.02% compared to Brainsway's net margin of 15.65%. LeMaitre Vascular's return on equity of 15.63% beat Brainsway's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Brainsway	15.65%	12.74%	8.17%
LeMaitre Vascular	25.02%	15.63%	10.06%

Summary

LeMaitre Vascular beats Brainsway on 9 of the 15 factors compared between the two stocks.

How does Brainsway compare to Inspire Medical Systems?

Inspire Medical Systems (NYSE:INSP) and Brainsway (NASDAQ:BWAY) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, valuation, risk, earnings, profitability, institutional ownership and analyst recommendations.

Inspire Medical Systems presently has a consensus target price of $66.50, indicating a potential downside of 13.47%. Brainsway has a consensus target price of $18.20, indicating a potential upside of 33.73%. Given Brainsway's stronger consensus rating and higher probable upside, analysts plainly believe Brainsway is more favorable than Inspire Medical Systems.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inspire Medical Systems	3 Sell rating(s)	11 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.21
Brainsway	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71

94.9% of Inspire Medical Systems shares are owned by institutional investors. Comparatively, 30.1% of Brainsway shares are owned by institutional investors. 2.2% of Inspire Medical Systems shares are owned by company insiders. Comparatively, 19.0% of Brainsway shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Inspire Medical Systems had 6 more articles in the media than Brainsway. MarketBeat recorded 7 mentions for Inspire Medical Systems and 1 mentions for Brainsway. Inspire Medical Systems' average media sentiment score of 1.23 beat Brainsway's score of 0.88 indicating that Inspire Medical Systems is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inspire Medical Systems	5 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Brainsway	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Brainsway has a net margin of 15.65% compared to Inspire Medical Systems' net margin of 15.03%. Brainsway's return on equity of 12.74% beat Inspire Medical Systems' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inspire Medical Systems	15.03%	8.64%	7.45%
Brainsway	15.65%	12.74%	8.17%

Inspire Medical Systems has a beta of 0.7, suggesting that its stock price is 30% less volatile than the broader market. Comparatively, Brainsway has a beta of 1.25, suggesting that its stock price is 25% more volatile than the broader market.

Inspire Medical Systems has higher revenue and earnings than Brainsway. Inspire Medical Systems is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inspire Medical Systems	$911.98M	2.44	$145.42M	$4.62	16.63
Brainsway	$52.22M	10.48	$7.57M	$0.44	30.93

Summary

Brainsway beats Inspire Medical Systems on 10 of the 17 factors compared between the two stocks.

Get Brainsway News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BWAY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BWAY vs. The Competition

Export

Metric	Brainsway	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$547.23M	$5.55B	$7.24B	$13.19B
Dividend Yield	N/A	1.80%	2.57%	12.81%
P/E Ratio	30.93	25.34	275.49	25.40
Price / Sales	10.48	72.49	646.01	89.45
Price / Cash	58.13	32.64	76.25	51.42
Price / Book	7.28	5.69	10.46	6.33
Net Income	$7.57M	$151.55M	$3.49B	$358.33M
7 Day Performance	-2.30%	0.66%	0.59%	1.12%
1 Month Performance	-9.08%	-3.33%	-1.74%	-2.39%
1 Year Performance	75.95%	6.79%	18.13%	5.35%

Brainsway Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BWAY Brainsway	4.6423 of 5 stars	$13.61 +0.6%	$18.20 +33.7%	+76.0%	$547.23M	$52.22M	30.93	129
ESTA Establishment Labs	2.8702 of 5 stars	$75.00 +1.0%	$100.25 +33.7%	+75.6%	$2.23B	$211.08M	N/A	1,004
NVCR NovoCure	2.4026 of 5 stars	$17.48 -2.6%	$21.20 +21.3%	+31.5%	$2.03B	$655.35M	N/A	1,605	News Coverage
BFLY Butterfly Network	1.3332 of 5 stars	$7.54 +2.4%	$5.56 -26.2%	+325.6%	$2.00B	$97.61M	N/A	460	Options Volume
LMAT LeMaitre Vascular	4.9053 of 5 stars	$79.51 -1.4%	$110.60 +39.1%	-14.5%	$1.82B	$249.60M	27.90	490	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BWAY) was last updated on 9/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Brainsway (BWAY) Competitors

BWAY vs. ESTA, NVCR, BFLY, LMAT, and INSP

How does Brainsway compare to Establishment Labs?

Summary

How does Brainsway compare to NovoCure?

Summary

How does Brainsway compare to Butterfly Network?

Summary

How does Brainsway compare to LeMaitre Vascular?

Summary

How does Brainsway compare to Inspire Medical Systems?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BWAY vs. The Competition

Brainsway Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Brainsway (BWAY) Competitors

BWAY vs. ESTA, NVCR, BFLY, LMAT, and INSP

How does Brainsway compare to Establishment Labs?

Do institutionals & insiders hold more shares of BWAY or ESTA?

Does the media favor BWAY or ESTA?

Which has more volatility & risk, BWAY or ESTA?

Do analysts recommend BWAY or ESTA?

Which has preferable earnings & valuation, BWAY or ESTA?

Is BWAY or ESTA more profitable?

Summary

How does Brainsway compare to NovoCure?

Which has more risk and volatility, NVCR or BWAY?

Do institutionals and insiders have more ownership in NVCR or BWAY?

Do analysts rate NVCR or BWAY?

Is NVCR or BWAY more profitable?

Which has better earnings & valuation, NVCR or BWAY?

Does the media refer more to NVCR or BWAY?

Summary

How does Brainsway compare to Butterfly Network?

Which has preferable earnings & valuation, BFLY or BWAY?

Do institutionals & insiders have more ownership in BFLY or BWAY?

Is BFLY or BWAY more profitable?

Do analysts prefer BFLY or BWAY?

Which has more volatility & risk, BFLY or BWAY?

Does the media favor BFLY or BWAY?

Summary

How does Brainsway compare to LeMaitre Vascular?

Does the media refer more to BWAY or LMAT?

Do institutionals & insiders believe in BWAY or LMAT?

Which has more volatility & risk, BWAY or LMAT?

Do analysts rate BWAY or LMAT?

Which has better earnings & valuation, BWAY or LMAT?

Is BWAY or LMAT more profitable?

Summary

How does Brainsway compare to Inspire Medical Systems?

Do analysts rate INSP or BWAY?

Do institutionals and insiders believe in INSP or BWAY?

Does the media favor INSP or BWAY?

Is INSP or BWAY more profitable?

Which has more volatility & risk, INSP or BWAY?

Which has preferable valuation and earnings, INSP or BWAY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BWAY vs. The Competition

Brainsway Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools